Molecular Cancer (Mar 2007)

Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model

  • Ong John M,
  • Prosolovich Ksenia,
  • Espinoza Andres,
  • Konda Bindu M,
  • Wang Xiao,
  • Sacapano Manuel R,
  • Yin Dali,
  • Ko MinHee K,
  • Yuan Xiangpeng,
  • Hu Jinwei,
  • Irvin Dwain,
  • Black Keith L

DOI
https://doi.org/10.1186/1476-4598-6-22
Journal volume & issue
Vol. 6, no. 1
p. 22

Abstract

Read online

Abstract Background The blood-brain tumor barrier (BTB) impedes the delivery of therapeutic agents to brain tumors. While adequate delivery of drugs occurs in systemic tumors, the BTB limits delivery of anti-tumor agents into brain metastases. Results In this study, we examined the function and regulation of calcium-activated potassium (KCa) channels in a rat metastatic brain tumor model. We showed that intravenous infusion of NS1619, a KCa channel agonist, and bradykinin selectively enhanced BTB permeability in brain tumors, but not in normal brain. Iberiotoxin, a KCa channel antagonist, significantly attenuated NS1619-induced BTB permeability increase. We found KCa channels and bradykinin type 2 receptors (B2R) expressed in cultured human metastatic brain tumor cells (CRL-5904, non-small cell lung cancer, metastasized to brain), human brain microvessel endothelial cells (HBMEC) and human lung cancer brain metastasis tissues. Potentiometric assays demonstrated the activity of KCa channels in metastatic brain tumor cells and HBMEC. Furthermore, we detected higher expression of KCa channels in the metastatic brain tumor tissue and tumor capillary endothelia as compared to normal brain tissue. Co-culture of metastatic brain tumor cells and brain microvessel endothelial cells showed an upregulation of KCa channels, which may contribute to the overexpression of KCa channels in tumor microvessels and selectivity of BTB opening. Conclusion These findings suggest that KCa channels in metastatic brain tumors may serve as an effective target for biochemical modulation of BTB permeability to enhance selective delivery of chemotherapeutic drugs to metastatic brain tumors.